Scarica l'app Stockscreener
188.05
1.97%
-3.77
Dopo l'orario di chiusura:
188.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
TD Asset Management Inc Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Rafferty Asset Management LLC Lowers Stake in Biogen Inc. $BIIB - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Has $43.06 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment - simplywall.st
Biogen (BIIB) Receives a Buy from RBC Capital - The Globe and Mail
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Generali Investments Management Co LLC Grows Holdings in Biogen Inc. $BIIB - MarketBeat
Fox Run Management L.L.C. Has $976,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Hold" by Brokerages - MarketBeat
AMETHYST trial of litifilimab making "strong progress," Biogen says - Lupus News Today
Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says - marketscreener.com
Primecap Management Co. CA Has $2.09 Billion Stock Holdings in Biogen Inc. $BIIB - MarketBeat
10,006 Shares in Biogen Inc. $BIIB Acquired by K.J. Harrison & Partners Inc - MarketBeat
Biogen Stock After Alzheimer’s Shake-Up: Bargain or Value Trap? - AD HOC NEWS
Biogen to Participate in the TD Cowen 46th Annual Health Care Conference - Biogen
Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - AOL.com
Dementia Treatment Market Booming with Rapid Growth Through - openPR.com
Biogen Pharmachem Industries Ltd is Rated Strong Sell - Markets Mojo
How (BIIB) Movements Inform Risk Allocation Models - Stock Traders Daily
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards - CSRwire
Biogen-Funded Collaboration with Americares and Harvard Chan C-CHANGE Recognized by the Clinton Global Initiative - CSRwire
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative - CSRwire
Biogen Included in 2022 Bloomberg Gender-Equality Index - CSRwire
Skandinaviska Enskilda Banken AB publ Has $4.07 Million Position in Biogen Inc. $BIIB - MarketBeat
Barclays Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Barclays Initiates Coverage of Biogen (BIIB) with Equal-Weight Recommendation - Nasdaq
Beyond The Numbers: 21 Analysts Discuss Biogen Stock - Benzinga
Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst - TipRanks
Barclays initiates Biogen stock coverage with $185 price target By Investing.com - Investing.com Nigeria
Biogen (BIIB) Receives New Analyst Coverage with Equal-Weight Ra - GuruFocus
Barclays initiates Biogen stock coverage with $185 price target - Investing.com
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB - MarketBeat
New Biogen Chair Freire May Recast Partnerships And Capital Priorities - Yahoo Finance
Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection - TradingView
Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - Yahoo Finance
Assessing Biogen (BIIB) Valuation As Shares Gain 18.1% In 30 Days And 42% Over One Year - Yahoo Finance
Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism - simplywall.st
NEOS Investment Management LLC Boosts Position in Biogen Inc. $BIIB - MarketBeat
Multiple Sclerosis Therapeutics Market to Reach USD 46.22 - openPR.com
Aberdeen Group plc Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Biogen head of pharm ops Murphy buys $585 in stock By Investing.com - Investing.com Canada
Biogen head of pharm ops Murphy buys $585 in stock - Investing.com
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush lifts PT on Biogen Inc. (BIIB) to $187 from $178 – here’s why - MSN
5,611 Shares in Biogen Inc. $BIIB Purchased by Caprock Group LLC - MarketBeat
Biogen Stock Performance 2026 | Financial Results & Analyst RatingsNews and Statistics - IndexBox
What Price Targets Have Wall Street Analysts Set for Biogen Shares? - Bitget
What Are Wall Street Analysts' Target Price for Biogen Stock? - Yahoo Finance
AlphaQuest LLC Sells 10,789 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Appoints Dr. Gabriela Freire as Board Chair While Immunic Inc. Searches for New CEO - geneonline.com
Early Diagnosis Kit for Alzheimer's Disease Market Outlook - openPR.com
Rhumbline Advisers Has $40.51 Million Position in Biogen Inc. $BIIB - MarketBeat
What are Biogen Inc.’s recent SEC filings showingMarket Risk Report & Growth Oriented Trade Recommendations - mfd.ru
Biogen’s New Therapies Surpass US$1 Billion In Sales Might Change The Case For Investing In BIIB - simplywall.st
LSV Asset Management Grows Position in Biogen Inc. $BIIB - MarketBeat
Oppenheimer & Co. Inc. Has $1.91 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Clinically Isolated Syndrome Treatment Market Size 2030 US$ 2.4 - openPR.com
BIIB: Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs - TradingView
Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus - MarketBeat
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why - Insider Monkey
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178Here's Why - Finviz
Is Biogen (NASDAQ:BIIB) Using Too Much Debt? - 富途牛牛
1.41%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):